Anti-hypertensive drugs
Phase 3Small molecule
Anti-hypertensive drugs is one of 62 small molecule programs targeting Angina Pectoris. It is currently in Phase 3.
2
Indications
3
Total Trials
1
Active Trials
61
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
566 competitors in Hypertension
#DrugCompanyPhaseTrials
1Anti-hypertensive drugs
UUniversity of Pavia
Phase 3
Edarbi
TakedaPreclinical
Benicar
NovartisPreclinical
Apresoline
NovartisPreclinical
Edarbi
TakedaPreclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Disalcid
JJoslin Diabetes Center
Preclinical
Inderal
Mylan Pharmaceuticals IncPreclinical
Atorvastatin Calcium
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Postmenopausal Women1 trial
Effect of DASH Diet and Progressive Muscle Relaxation on Cardiovascular Risks in Postmenopausal Women
Recruiting·—·N/A·NCT06600347·90 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anti-hypertensive drugs. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Pavia